GB201816369D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB201816369D0
GB201816369D0 GBGB1816369.1A GB201816369A GB201816369D0 GB 201816369 D0 GB201816369 D0 GB 201816369D0 GB 201816369 A GB201816369 A GB 201816369A GB 201816369 D0 GB201816369 D0 GB 201816369D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1816369.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sareum Ltd
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Priority to GBGB1816369.1A priority Critical patent/GB201816369D0/en
Publication of GB201816369D0 publication Critical patent/GB201816369D0/en
Priority to DK19794095.0T priority patent/DK3864009T3/da
Priority to PCT/EP2019/077118 priority patent/WO2020074461A1/en
Priority to EP19794095.0A priority patent/EP3864009B1/en
Priority to CA3111049A priority patent/CA3111049A1/en
Priority to PL19794095.0T priority patent/PL3864009T3/pl
Priority to CN201980066166.4A priority patent/CN113056456B/zh
Priority to US17/283,151 priority patent/US12187716B2/en
Priority to KR1020217013504A priority patent/KR102844196B1/ko
Priority to BR112021006424A priority patent/BR112021006424A2/pt
Priority to FIEP19794095.0T priority patent/FI3864009T3/fi
Priority to SG11202102490TA priority patent/SG11202102490TA/en
Priority to ES19794095T priority patent/ES3021420T3/es
Priority to IL281599A priority patent/IL281599B2/en
Priority to JP2021543577A priority patent/JP7383030B2/ja
Priority to AU2019359320A priority patent/AU2019359320B2/en
Priority to MX2021003929A priority patent/MX2021003929A/es
Priority to PT197940950T priority patent/PT3864009T/pt
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1816369.1A 2018-10-08 2018-10-08 Pharmaceutical compounds Ceased GB201816369D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB1816369.1A GB201816369D0 (en) 2018-10-08 2018-10-08 Pharmaceutical compounds
PT197940950T PT3864009T (pt) 2018-10-08 2019-10-07 Inibidores da tyk2 quinase
KR1020217013504A KR102844196B1 (ko) 2018-10-08 2019-10-07 Tyk2 키나제 억제제
FIEP19794095.0T FI3864009T3 (fi) 2018-10-08 2019-10-07 TYK2-kinaasi-inhibiittoreita
EP19794095.0A EP3864009B1 (en) 2018-10-08 2019-10-07 Tyk2 kinase inhibitors
CA3111049A CA3111049A1 (en) 2018-10-08 2019-10-07 Tyk2 kinase inhibitors
PL19794095.0T PL3864009T3 (pl) 2018-10-08 2019-10-07 Inhibitory kinazy tyk2
CN201980066166.4A CN113056456B (zh) 2018-10-08 2019-10-07 Tyk2激酶抑制剂
US17/283,151 US12187716B2 (en) 2018-10-08 2019-10-07 TYK2 kinase inhibitors
DK19794095.0T DK3864009T3 (da) 2018-10-08 2019-10-07 Tyk2-kinasehæmmere
BR112021006424A BR112021006424A2 (pt) 2018-10-08 2019-10-07 inibidores de quinase tyk2
PCT/EP2019/077118 WO2020074461A1 (en) 2018-10-08 2019-10-07 Tyk2 kinase inhibitors
SG11202102490TA SG11202102490TA (en) 2018-10-08 2019-10-07 Tyk2 kinase inhibitors
ES19794095T ES3021420T3 (en) 2018-10-08 2019-10-07 Tyk2 kinase inhibitors
IL281599A IL281599B2 (en) 2018-10-08 2019-10-07 2-(2,6-dichlorophenyl)-5-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)anilino]-1,3-oxazole-4- carboxamide, and its 3-fluoro derivative
JP2021543577A JP7383030B2 (ja) 2018-10-08 2019-10-07 Tyk2キナーゼ阻害剤
AU2019359320A AU2019359320B2 (en) 2018-10-08 2019-10-07 TYK2 kinase inhibitors
MX2021003929A MX2021003929A (es) 2018-10-08 2019-10-07 Compuestos farmaceuticos.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1816369.1A GB201816369D0 (en) 2018-10-08 2018-10-08 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB201816369D0 true GB201816369D0 (en) 2018-11-28

Family

ID=64397425

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1816369.1A Ceased GB201816369D0 (en) 2018-10-08 2018-10-08 Pharmaceutical compounds

Country Status (18)

Country Link
US (1) US12187716B2 (https=)
EP (1) EP3864009B1 (https=)
JP (1) JP7383030B2 (https=)
KR (1) KR102844196B1 (https=)
CN (1) CN113056456B (https=)
AU (1) AU2019359320B2 (https=)
BR (1) BR112021006424A2 (https=)
CA (1) CA3111049A1 (https=)
DK (1) DK3864009T3 (https=)
ES (1) ES3021420T3 (https=)
FI (1) FI3864009T3 (https=)
GB (1) GB201816369D0 (https=)
IL (1) IL281599B2 (https=)
MX (1) MX2021003929A (https=)
PL (1) PL3864009T3 (https=)
PT (1) PT3864009T (https=)
SG (1) SG11202102490TA (https=)
WO (1) WO2020074461A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005114D0 (en) * 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
IL153246A0 (en) 2000-06-28 2003-07-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
DE60128731T2 (de) 2000-10-30 2008-02-07 Janssen Pharmaceutica N.V. Tripeptidylpeptidase-hemmer
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
EP1684750B1 (en) 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
JP5222561B2 (ja) 2005-10-07 2013-06-26 キッセイ薬品工業株式会社 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
ES2352320T3 (es) 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
WO2008024980A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
JP5478488B2 (ja) 2007-06-20 2014-04-23 メルク・シャープ・アンド・ドーム・コーポレーション Janusキナーゼの阻害剤
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2299816B1 (en) 2008-06-18 2013-11-13 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8420695B2 (en) 2008-07-09 2013-04-16 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
US20130096104A1 (en) 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN103987713A (zh) 2011-10-12 2014-08-13 阵列生物制药公司 5,7-取代的咪唑并[1,2-c]嘧啶
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
EP3040336B1 (en) * 2012-03-02 2020-04-08 Sareum Limited Compounds for use in treating tyk2 kinase mediated conditions
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
LT3495358T (lt) 2012-11-08 2022-05-25 Bristol-Myers Squibb Company Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai
MX369974B (es) 2013-09-03 2019-11-27 Sareum Ltd Compuestos farmaceuticos.
JP6310767B2 (ja) 2014-05-13 2018-04-11 日本電子株式会社 自動分析装置及びノズル洗浄方法
NO2721710T3 (https=) 2014-08-21 2018-03-31
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound

Also Published As

Publication number Publication date
JP7383030B2 (ja) 2023-11-17
CA3111049A1 (en) 2020-04-16
CN113056456A (zh) 2021-06-29
EP3864009A1 (en) 2021-08-18
MX2021003929A (es) 2021-06-04
KR20210076036A (ko) 2021-06-23
IL281599A (en) 2021-05-31
AU2019359320B2 (en) 2024-04-04
FI3864009T3 (fi) 2025-03-24
DK3864009T3 (da) 2025-03-17
JP2022514799A (ja) 2022-02-15
IL281599B2 (en) 2024-10-01
IL281599B1 (en) 2024-06-01
PT3864009T (pt) 2025-04-23
ES3021420T3 (en) 2025-05-26
US12187716B2 (en) 2025-01-07
EP3864009B1 (en) 2025-02-19
WO2020074461A1 (en) 2020-04-16
CN113056456B (zh) 2023-06-13
PL3864009T3 (pl) 2025-04-22
BR112021006424A2 (pt) 2021-07-06
KR102844196B1 (ko) 2025-08-07
US20210387981A1 (en) 2021-12-16
AU2019359320A1 (en) 2021-03-18
SG11202102490TA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
IL276232A (en) pharmaceutical compounds
GB201911928D0 (en) Pharmaceutical compounds
GB2572126B (en) Pharmaceutical
GB2569961B (en) Pharmaceutical
GB2572125B (en) Pharmaceutical
GB201810245D0 (en) Pharmaceutical compounds
EP3638658C0 (en) PHARMACEUTICAL COMPOUNDS
GB201810239D0 (en) Pharmaceutical compounds
GB201704714D0 (en) Pharmaceutical compounds
GB201819961D0 (en) Pharmaceutical compounds
GB201911944D0 (en) Pharmaceutical compounds
GB201704965D0 (en) Pharmaceutical compounds
GB201703881D0 (en) Pharmaceutical compounds
GB201819960D0 (en) Pharmaceutical compounds
GB201915273D0 (en) Pharmaceutical compounds
GB201914910D0 (en) Pharmaceutical compounds
GB201706806D0 (en) Pharmaceutical compounds
GB201915932D0 (en) Pharmaceutical compounds
GB201801562D0 (en) Pharmaceutical compounds
GB201711704D0 (en) Pharmaceutical compounds
SI3728220T1 (sl) Farmacevtske spojine
IL277334A (en) Pharmaceutical combinations
GB201704966D0 (en) Pharmaceutical compounds
IL291570A (en) Pharmaceutical preparations
GB201800378D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)